Autosomal recessive polycystic kidney disease, ARPKD, is a rare genetic disorder occurring in approximately 1 in 20,000 children. It affects boys and girls equally and can cause death in the first month of life. If a child with ARPKD survives the newborn period, the chances of survival are good. For these children, approximately one-third will need dialysis or transplantation by the age of 10.
What can I expect if my child has ARPKD?
Previously thought to be a fatal condition, the prognosis for children with ARPKD has improved dramatically. Twenty years ago, only half of the children born with the disease survived to their 10th birthday, but now that percentage has increased to 85. The immediate life-threatening issue for infants with ARPKD is lung immaturity. Lung immaturity is caused in part by insufficient amniotic fluid, produced by the kidneys, due to poor prenatal renal function. Severely enlarged kidneys caused by ARPKD also limit breathing by preventing adequate lung expansion. Death in the neonatal period can be as high as 30 to 50 percent. If an infant with ARPKD survives this critical period, kidney failure can become the most prominent life threatening issue. When the newborn’s life isn’t at risk, the biggest health concerns are often regulating blood pressure and the chemical balance of blood. The improved prognosis for ARPKD may be attributed to improved prenatal sonogram technology which allows doctors to diagnose many cases of ARPKD prior to birth. Accordingly, the birth of an affected child is better planned so the necessary specialists can be alerted. Importantly, the doctors are able to discuss with the parents what they should expect once the baby is born, advising them that the infant may need a breathing tube, may require dialysis, may have severe liver disease, and will require multiple evaluations and treatments to handle associated complications.
Learn more about ARPKD patient registry
The University of Alabama at Birmingham Hepato/Renal Fibrocystic Disease Core Center (UAB HRFDCC) has established a NIDDK-funded interdisciplinary center of excellence in PKD-related research, with specific emphasis on ARPKD. Among the four cores, the UAB HRFDCC includes the Core A: Hepato/Renal Fibrocystic Disease Translational Resource, a Core resource designed to develop a unique set of clinical, genetic, and educational resources for autosomal recessive polycystic kidney disease (ARPKD) and other recessive forms of renal cystic disease.